This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): TC-2216
Description: TC-2216 is a oral compound discovered using Targacept’s proprietary drug design platform known as Pentad. The compound targets specific neuronal nicotinic receptors (NNRs), a class of receptors found in the central nervous system that play a role in regulating nervous system activity. TC-2216 selectively inhibits the a4ß2 NNR, which may modulate the release of neurotransmitters that are involved in mood regulation.
Targacept and Catalyst
In March 2015, Targacept and Catalyst Biosciences jointly announced that they have entered into a definitive agreement to merge the two companies. The combined entity, to be named Catalyst Biosciences, will harness the catalytic power of engineered human proteases to develop next-generation biopharmaceuticals with improved efficacy and therapeutic index to treat major diseases.
In March 2015, Targacept and Catalyst entered into an amendment to the definitive agreement to merge the two companies.
Additional information available to subscribers only: